

Confirmed Speakers

Confirmed Invited Speakers

T15 - Ring Construction by Pd-catalyzed C(sp³)-H Activation



Olivier BAUDOUIN
(UNIVERSITY OF BASEL, Basel, Switzerland)

T10 - Azidoperfluoroalkanes - Neglected, Stable and Useful Fluorinated Synthons



Petr BEIER
(ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, Prague, Czech Republic)

T02 - Next-Generation Small Molecule Therapeutics



James E BRADNER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States)

T03 - Drugging the Undruggable



Mark BUNNAGE
(VERTEX PHARMACEUTICALS, Boston, United States)

T07 - Beta-secretase Inhibitors as a Therapy for Alzheimer's Disease – Where Are We Now?



Roland BÜRLI
(ASTRAZENECA, Cambridge, United Kingdom)

T25 - More Options, More Complexity: Medicinal Chemistry Mastering Mixed Modalities



Werngard CZECHTIZKY
(SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt, Germany)

T22 - Collaborative Academic/Industrial Research Under the Umbrella of the NSF Center for Selective C-H Functionalization



Huw DAVIES
(EMORY UNIVERSITY, Atlanta, United States)

T24 - Synthetic, Mechanistic and Computational Studies on Reactions of Interest



Scott E. DENMARK
(UNIVERSITY OF ILLINOIS, Urbana, United States)

T13 - Isosteric-Switch Strategies: New Concepts and Recent Advances

Confirmed Speakers



Thomas C. FESSARD
(SPIROCHEM AG, Zurich, Switzerland)

T26 - DNA Repair Inhibition in Cancer Therapy: DNA-PK Inhibitor M3814



Thomas FUCHSS
(MERCK KGAA, Darmstadt, Germany)

T18 - Exploiting Physical Organic Principles in Reaction Design



Ryan GILMOUR
(UNIVERSITY OF MÜNSTER, Münster, Germany)

T27 - Late Stage 18F-Fluorination for PET Imaging



Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

T19 - Automation, Integration and Miniaturization In Drug Discovery Synthesis



Guido KOCH
(NOVARTIS PHARMA AG, Basel, Switzerland)

T12 - Organic Synthesis with Rearrangements - Adventures in Total Synthesis



Nuno MAULIDE
(UNIVERSITY OF VIENNA, Vienna, Austria)

T11 - HIV-1 Maturation Inhibitors



Nicholas MEANWELL
(BRISTOL-MYERS SQUIBB, Wallingford, United States)

T06 - Single Electron Processes to Enable Organic Synthesis



Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

T08 - Idea2Data: Augmenting Drug Discovery Efforts through Synthetic Reaction Data Mining and Automation



Christos A. NICOLAOU
(ELI LILLY, Indianapolis, United States)

T21 - With Asymmetric Hydrogenation towards a Scalable, Stereoselective Synthesis of Bitopertin

Confirmed Speakers



Michelangelo SCALONE
(F. HOFFMANN-LA ROCHE AG, Basel, Switzerland)

T14 - Iron(III)-Catalyzed Carbonyl-Olefin Metathesis



Corinna SCHINDLER
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

T17 - Adventures in Catalysis: from Mechanisms to Applications



Franziska SCHOENEBECK
(RWTH AACHEN, Aachen, Germany)

T23 - Strategies towards Increasing the 3-Dimensionality of the Medicinal Chemistry Design Space



Antonia F. STEPAN
(PFIZER, Cambridge, United States)

T09 - A RaPID Way to Discover Pseudo-natural Peptides



Hiroaki SUGA
(UNIVERSITY OF TOKYO, Tokyo, Japan)

Opening Lecture

T01 - Photochemistry and Photopharmacology in Medicine



Dirk TRAUNER
(NEW YORK UNIVERSITY, New York, United States)

T20 - Design and Evolution of New Biocatalysts for Organic Synthesis



Nicholas John TURNER
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

T16 - Merck Drug Discovery through Enabling Capabilities



Petr VACHAL
(MSD, Kenilworth, United States)

T04 - Bioinspired Asymmetric Catalysis



Helma WENNEMERS
(ETH ZURICH, Zürich, Switzerland)

T05 - Strategies to Facilitate the Discovery of Novel CNS PET Ligands

Confirmed Speakers



Lei ZHANG
(PFIZER, Cambridge, United States)

Oral Communications

OC09 - Development of Synthesis Strategies to DNA-Encoded Compound Libraries - of a Chemoresistant Sequence, and Micellar Nanoreactors



Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany)

OC06 - Expanding Screening Decks by Innovative MCR Scaffolds



Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

OC02 - Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6



Peter ETTMAYER
(BOEHRINGER-INGELHEIM, Vienna, Austria)

EFMC Prize for a Young Medicinal Chemist in Academia

OC10 - Nature-Derived Peptides as Pharmacological Tools to Design Novel Therapeutics



Christian W. GRUBER
(MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria)

EFMC Prize for a Young Medicinal Chemist in Industry:

OC11 - The Development of non-BET Bromodomain Chemical Probes



Phil HUMPHREYS
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

PRIZE winner EFMC-YMCS 2016

OC04 - Development of Highly Selective and Reversible Diacylglycerol Lipase Inhibitors



Freek JANSSEN
(LEIDEN UNIVERSITY, Nijmegen, The Netherlands)

OC01 - Stereoselective Peptide Modifications – Efficient Tools for Natural Product and Drug Synthesis



Uli KAZMAIER
(SAARLAND UNIVERSITY, Saarbrücken, Germany)

OC03 - Mimicking Nature Complexity with 3D-Fragments Assembly

Confirmed Speakers



Hugues LEMOINE
(EDELIRIS, LYON, France)

OC12 - Discovery of UCB0942, the First Rationally Designed Antiepileptic Drug with a Dual Mechanism of Action for the Treatment of Drug-Resistant Epilepsy



Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)

OC07 - The Discovery of Soluble Guanylate Cyclase Stimulators for the Treatment of Pulmonary Arterial Hypertension



Subharekha RAGHAVAN
(MSD, Kenilworth, New Jersey, United States)

OC05 - Discovery of RG7314, a Vasopressin 1a Receptor Antagonist for the Treatment of Social Communication Deficits in Autism Spectrum Disorders



Patrick SCHNIDER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

OC08 - Exploring New Methods for Facile Synthesis of Some Biologically Interesting Molecules



Ming-Hua XU
(SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai, China)